Attenuated Dose Dasatinib in Newly Diagnosed Chronic Myeloid Leukemia Chronic Phase Patients in India.

达沙替尼 医学 伊马替尼 内科学 髓系白血病 酪氨酸激酶抑制剂 肿瘤科 慢性粒细胞白血病 酪氨酸激酶 甲磺酸伊马替尼 白血病 癌症 受体
作者
Rayaz Ahmed,Reema Singh,Jyotsna Kapoor,Narendra Agrawal,Dinesh Bhurani,Rohan Halder
出处
期刊:Clinical Lymphoma, Myeloma & Leukemia [Elsevier]
卷期号:23 (2): e71-e77
标识
DOI:10.1016/j.clml.2022.11.006
摘要

BCR-ABL Tyrosine kinase inhibitors (TKI's) are most successful of targeted therapies and are currently considered the cornerstone in the management of patients with chronic myeloid leukemia (CML). A recent study reported excellent outcomes of Dasatinib 50mg with better sustained response. Therefore, we aim to evaluate the molecular responses and safety of upfront Dasatinib 50mg in Indian CML-Chronic Phase patients.It was an observational single-centre study. CML-CP patients started on Dasatinib 50mg daily were offered to participate in this study. Data of imatinib was collected retrospectively as a comparator group.Between June 2020 to Feb 2022, fifty patients were included in the dasatinib 50mg once daily group. Median age was 40 yrs. ranging from (19 to73) years. At a median follow up of 9.2 months, 49 patients completed three months treatment, out of which 48 patients were evaluated as one patient stopped medication after a month due to financial constraints. The response rate at three months for dasatinib 50mg daily and Imatinib were 68.75% and 69.7% respectively. At 12 months, 68% and 66.6% patients achieved major molecular response [MMR] in dasatinib 50mg and imatinib groups respectively.In conclusion, low dose dasatinib is safe and effective as an upfront therapy in CML-CP. Early molecular response [EMR] rates were comparable in low dose dasatinib and imatinib arm but deep molecular responses were significantly higher in low dose dasatinib arm. Dasatinib, taken daily at a dose of 50mg, may offer a new, alternative choice as generic versions are available now for frontline therapy in CML-CP.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
水文小白完成签到,获得积分10
2秒前
友好的牛排完成签到,获得积分10
2秒前
aleilei完成签到 ,获得积分10
6秒前
倪小呆完成签到 ,获得积分10
7秒前
昵称完成签到 ,获得积分10
7秒前
追风少年完成签到 ,获得积分10
8秒前
SH123完成签到 ,获得积分10
10秒前
ken131完成签到 ,获得积分10
10秒前
多托郭完成签到 ,获得积分10
11秒前
Murphy完成签到,获得积分10
13秒前
15秒前
务实青筠完成签到 ,获得积分10
16秒前
33应助吕培森采纳,获得10
17秒前
小宝爸爸完成签到 ,获得积分10
18秒前
努力学习的阿文完成签到,获得积分10
19秒前
Wang发布了新的文献求助10
21秒前
WANG完成签到,获得积分10
22秒前
liyan完成签到 ,获得积分10
28秒前
冰留完成签到 ,获得积分10
30秒前
科研小郭完成签到,获得积分10
31秒前
i2stay完成签到,获得积分10
33秒前
aaa0001984完成签到,获得积分0
33秒前
小大巫完成签到,获得积分10
37秒前
40秒前
稳重母鸡完成签到 ,获得积分10
42秒前
巫巫巫巫巫完成签到 ,获得积分10
47秒前
我和你完成签到 ,获得积分10
50秒前
1分钟前
涨芝士完成签到 ,获得积分10
1分钟前
老白完成签到,获得积分10
1分钟前
诚心的水杯完成签到 ,获得积分10
1分钟前
Tim完成签到 ,获得积分10
1分钟前
Syx_rcees完成签到,获得积分10
1分钟前
健忘数据线完成签到 ,获得积分10
1分钟前
御风完成签到,获得积分10
1分钟前
Pig-prodigy完成签到 ,获得积分10
1分钟前
H-kevin.完成签到 ,获得积分10
1分钟前
EiketsuChiy完成签到 ,获得积分0
1分钟前
Grace159完成签到 ,获得积分10
1分钟前
GankhuyagJavzan完成签到,获得积分10
1分钟前
高分求助中
The late Devonian Standard Conodont Zonation 2000
The Lali Section: An Excellent Reference Section for Upper - Devonian in South China 1500
Nickel superalloy market size, share, growth, trends, and forecast 2023-2030 1000
Smart but Scattered: The Revolutionary Executive Skills Approach to Helping Kids Reach Their Potential (第二版) 1000
Mantiden: Faszinierende Lauerjäger Faszinierende Lauerjäger 800
PraxisRatgeber: Mantiden: Faszinierende Lauerjäger 800
A new species of Coccus (Homoptera: Coccoidea) from Malawi 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3244791
求助须知:如何正确求助?哪些是违规求助? 2888434
关于积分的说明 8252919
捐赠科研通 2556928
什么是DOI,文献DOI怎么找? 1385502
科研通“疑难数据库(出版商)”最低求助积分说明 650176
邀请新用户注册赠送积分活动 626303